Status:
NOT_YET_RECRUITING
A Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma
Lead Sponsor:
Keymed Biosciences Co.Ltd
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a multi-center, open-label, Phase 1/2 study to evaluate the safety, tolerability, Pharmacokinetics, pharmacodynamics and Preliminary Efficacy of CM313 in Subjects with Relapsed or Refractory M...
Eligibility Criteria
Inclusion
- Subjects age ≥ 18 years.
- Subjects diagnosed with multiple myeloma.
- Subjects with measurable lesions.
- Women of childbearing potential with negative pregnancy testing.
- Subjects voluntarily signed the Informed Consent Form and were able to comply with the provisions of this protocol.
Exclusion
- Previous treatment with any anti-CD38 therapy.
- Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose.
- Positive for human immunodeficiency virus (HIV) antibodies.
- Syphilis antibody positive.
Key Trial Info
Start Date :
February 28 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06126237
Start Date
February 28 2024
End Date
February 28 2026
Last Update
November 13 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.